Arylsulfonamides and uses related thereto

Details Arylsulfonamides and uses related thereto Arylsulfonamides and uses related thereto

2008-11-24

2010-11-16

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S400000

Reexamination Certificate

active

07834047

ABSTRACT:
Arylsulfonamide compounds of formula I are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders:

REFERENCES:
patent: 2003/0130287 (2003-07-01), Ackermann et al.
patent: 4112868 (1992-04-01), None
patent: 5148233 (1993-06-01), None
patent: WO 97/49695 (1997-12-01), None
patent: WO 98/53814 (1998-12-01), None
patent: WO 9906436 (1999-02-01), None
patent: WO 01/02375 (2001-01-01), None
patent: WO 01/77101 (2001-10-01), None
patent: WO 01/90090 (2001-11-01), None
patent: WO 01/90091 (2001-11-01), None
patent: WO 01/90092 (2001-11-01), None
patent: WO 03/002534 (2003-01-01), None
patent: WO 03/037890 (2003-05-01), None
patent: WO 03/44009 (2003-05-01), None
patent: WO 03/057225 (2003-07-01), None
patent: WO 2004/011410 (2004-02-01), None
patent: WO 2004/022561 (2004-03-01), None
patent: WO 2004/092164 (2004-10-01), None
patent: WO 2005/014589 (2005-02-01), None
Vippagunta et al. Advanced Drug Delivery Reviews, 2001, 48, 3-26.
Jantzen and Robinson (Modern Pharmaceutics, 1996, p. 596.
Itoh et al. Tetrahedron, 2001, 57(34), 7277-89.
Miyawaki et al. Nucleic Acids Symposium Series No. 35, 1996, 11-12.
Barn, et al., “Parallel Synthesis and Biological Activity of a New Class of High Affinity and Selective δ-Opioid Ligand”, Bioorganic & Medicinal Chemistry, 2001, vol. 9, pp. 2609-2624, XP-002351368.
Carloni et al.,Tetrahedron, 1995, 51 (45), pp. 12445-124521.
Habashita, et al., “Preparation of nitrogen-containing heterocylic compounds as CXCR4 regulators”, 2004, XP-002381677.
Ito, et al., “Preparation of (pyridylalkyl)amine derivatives as thromboxane A2 antagonists and thromboxane A2 synthetase inhibitors”, 1994, XP-002381676.
Jantzen and Robinson,Modem Pharmaceutics, 1996, pp. 596.
Souers, et al., “Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 3”, Bioorganic & Medicinal Chemistry Letters, 2004, vol. 14, pp. 4883-4886, XP-002351369.
Vippagunta et al.,Advanced Drug Delivery Reviews, 2001, 48, pp. 3-26.
Watabe, et al., “Preparation of (piperidinylalkoxy- or pyrrolidinylalkoxy)benzoic acid derivatives as hypolipemic agents”, 1992, XP-002381675.
The Supplemental Partial Search Report received in the related European Patent Application EP 04814971, dated May 29, 2009. (3 pgs.).
The Office Action received in the related Mexican Patent Application No. PA/a/2006/012143.

Affiliated with

Also associated with

Rating

Arylsulfonamides and uses related thereto does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Arylsulfonamides and uses related thereto, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylsulfonamides and uses related thereto will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4200444